Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,798.95 +825.08 (+1.31%) CMC Crypto 200
1,322.20 +45.22 (+3.54%)
STOK May 2024 12.500 call
| Previous close | 0.6000 |
| Open | 0.8000 |
| Bid | 0.4000 |
| Ask | 0.8000 |
| Strike | 12.50 |
| Expiry date | 2024-05-17 |
| Day's range | 0.4500 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 802 |
ZacksEarnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireStoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BEDFORD, Mass., April 29, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer. In this role, Mr. Leggett will be responsible for overseeing all aspects of the Company’s financial strategy and operations. Mr. Leggett succeeds Stephen Tulipano, CPA, MBA, who resigned his p
ZacksEarnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
